| Gene symbol | CCL1 | Synonyms | I-309, P500, SCYA1, SISe, TCA3 | Type of gene | protein-coding |
| Chromosome | 17 | Map location | 17q12 | dbXrefs | |
| Description | C-C motif chemokine ligand 1 | ||||
| GTO ID | GTC1415 |
| Trial ID | NCT01547897 |
| Disease | Type 2 Diabetes Mellitus | Albuminuria |
| Altered gene | CCL1 |
| Therapeutic/Target gene | Target gene |
| Therapy | Aptamer |
| Treatment | NOX-E36|Spiegelmer |
| Phase | Phase2 |
| Recruitment status | Completed |
| Title | A Phase IIa Study to Characterize the Effects of CCL2 Inhibition With the Spiegelmer NOX-E36 in Patients With Type 2 Diabetes Mellitus and Albuminuria |
| Year | 2012 |
| Country | Czech Republic|Germany|Hungary|Poland|Romania |
| Company sponsor | TME Pharma AG |
| Other ID(s) | SNOXE36C301|2011-005710-11 |
| Cohort1: NOX-E36 | |||||||||
|
|||||||||
| Cohort2: Placebo | |||||||||
|
|||||||||